Literature DB >> 26569584

Mutational Heterogeneity in Melanoma: An Inconvenient Truth.

Gregory A Chang1, David Polsky2.   

Abstract

Identification of oncogenic BRAF mutations in primary and metastatic melanomas supports a linear model of clonal evolution in cancer. Some mutational studies, however, have failed to identify BRAF mutations in metastatic tumors from patients with BRAFmutant primary melanomas. Using a combination of methods, Riveiro-Falkenbach et al. (2015) assert that technical issues, and not clonal heterogeneity, may explain prior discordant mutational results.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26569584     DOI： 10.1038/jid.2015.351

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


  19 in total

1.  Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.

Authors:  David Capper; Matthias Preusser; Antje Habel; Felix Sahm; Ulrike Ackermann; Genevieve Schindler; Stefan Pusch; Gunhild Mechtersheimer; Hanswalter Zentgraf; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2011-06-03       Impact factor: 17.088

2.  Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.

Authors:  Harkanwal Halait; Kelli Demartin; Sweta Shah; Stephen Soviero; Rachel Langland; Suzanne Cheng; Grantland Hillman; Lin Wu; H Jeffrey Lawrence
Journal:  Diagn Mol Pathol       Date:  2012-03

3.  Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?

Authors:  Mélanie Saint-Jean; Gaëlle Quéreux; Jean-Michel Nguyen; Lucie Peuvrel; Anabelle Brocard; Audrey Vallée; Anne-Chantal Knol; Amir Khammari; Marc G Denis; Brigitte Dréno
Journal:  J Invest Dermatol       Date:  2013-09-11       Impact factor: 8.551

4.  BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.

Authors:  Hanna Eriksson; Abdlsattar Zebary; Ismini Vassilaki; Katarina Omholt; Mehran Ghaderi; Johan Hansson
Journal:  JAMA Dermatol       Date:  2015-04       Impact factor: 10.282

5.  Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors.

Authors:  Erica Riveiro-Falkenbach; Cándida A Villanueva; María C Garrido; Yolanda Ruano; Rosa M García-Martín; Elena Godoy; Pablo L Ortiz-Romero; Juan J Ríos-Martín; Angel Santos-Briz; José L Rodríguez-Peralto
Journal:  J Invest Dermatol       Date:  2015-06-17       Impact factor: 8.551

6.  Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression.

Authors:  J Lin; Y Goto; H Murata; K Sakaizawa; A Uchiyama; T Saida; M Takata
Journal:  Br J Cancer       Date:  2011-01-11       Impact factor: 7.640

7.  Biological diversity in metastatic neoplasms: origins and implications.

Authors:  I J Fidler; I R Hart
Journal:  Science       Date:  1982-09-10       Impact factor: 47.728

8.  Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.

Authors:  Klaus J Busam; Cyrus Hedvat; Melissa Pulitzer; Andreas von Deimling; Achim A Jungbluth
Journal:  Am J Surg Pathol       Date:  2013-03       Impact factor: 6.394

9.  Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.

Authors:  Molly Yancovitz; Adam Litterman; Joanne Yoon; Elise Ng; Richard L Shapiro; Russell S Berman; Anna C Pavlick; Farbod Darvishian; Paul Christos; Madhu Mazumdar; Iman Osman; David Polsky
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

10.  Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.

Authors:  Michelle V Pearlstein; Daniel C Zedek; David W Ollila; Amanda Treece; Margaret L Gulley; Pamela A Groben; Nancy E Thomas
Journal:  J Cutan Pathol       Date:  2014-07-04       Impact factor: 1.587
View more
  2 in total

1.  Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.

Authors:  V Doma; S Kárpáti; E Rásó; T Barbai; J Tímár
Journal:  BMC Cancer       Date:  2019-08-07       Impact factor: 4.430

2.  Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy.

Authors:  Roei D Mazor; Ran Weissman; Judith Luckman; Liran Domachevsky; Eli L Diamond; Omar Abdel-Wahab; Shirley Shapira; Oshrat Hershkovitz-Rokah; David Groshar; Ofer Shpilberg
Journal:  Neurooncol Adv       Date:  2020-03-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.